Skip to product information
CAGRILINTIDE / SEMAGLUTIDE 5mg/5mg
  • CAGRILINTIDE / SEMAGLUTIDE 5mg/5mg
  • CAGRILINTIDE / SEMAGLUTIDE 5mg/5mg
CAGRILINTIDE / SEMAGLUTIDE 5mg/5mg

CAGRILINTIDE / SEMAGLUTIDE 5mg/5mg

The combination of Cagrilintide and Semaglutide represents a modern, dual-agonist approach to metabolic and appetite-regulation research. Pairing an amylin analogue (Cagrilintide) with a GLP-1 receptor agonist (Semaglutide) creates a synergistic metabolic profile that is currently at the forefront of global metabolic-health investigations. This peptide has ideal research in these categories:

  1. – Metabolic Enhancement & Weight Management
  2. – Appetite Regulation
  3. – Body Composition Support

Understanding This Peptide

Cagrilintide mimics the natural amylin hormone, which plays a role in satiety and gastric emptying. Semaglutide mimics GLP-1, influencing appetite, insulin signaling, and glycemic control. Together, they form a potent metabolic research framework that targets multiple satiety and energy-balance pathways simultaneously.

Mechanism of Action

Cagrilintide activates amylin receptors to slow gastric emptying and support satiety signaling. Semaglutide activates GLP-1 receptors to modulate appetite, insulin secretion, and metabolic stability. When combined, these peptides create a powerful dual pathway that enhances fullness, stabilizes metabolic responses, and promotes controlled energy utilization.

Scientific Interest

Researchers are interested in this combination due to its ability to activate two major appetite-regulating hormones at once, offering a multilayered metabolic approach. This pairing reflects the future of metabolic-modulating research and has rapidly become one of the most studied dual-peptide combinations worldwide.

Research Focus & Clinical Landscape

Active areas of investigation include:

  1. – appetite and satiety regulation
  2. – gastric-emptying response
  3. – insulin and glucose dynamics
  4. – metabolic rate and energy expenditure
  5. – body-composition outcomes
  6. – dual-agonist metabolic mechanisms

Large-scale clinical trials continue to evaluate the combination’s long-term effects and potential superiority over single-pathway peptides.

Quality, Craftsmanship & Purity

Both peptides are produced at high purity (>98%) in GMP-aligned facilities and verified through independent laboratory testing. The combination is prepared to support researchers studying advanced metabolic pathways.

Final Insight

The Cagrilintide/Semaglutide pairing stands at the frontier of modern metabolic research, offering a refined, powerful dual-pathway approach that continues to reshape understanding of appetite and energy regulation.

You may also like

Product disclaimers: This compound is supplied for in vitro laboratory research, including assay development, scientific research protocols, peptide characterization, and academic or industrial research environments. Store lyophilized peptide at −20°C. Store reconstituted solution at 2–8°C. Keep out of direct sunlight and avoid repeated freeze–thaw cycles. This product should be handled only by qualified research personnel using appropriate laboratory safety procedures, PPE, and containment tools. This product is not intended for human consumption, medical, therapeutic, diagnostic, veterinary, or cosmetic use, including injection or topical application. This product is not approved by the FDA and is not intended to diagnose, treat, cure, or prevent any disease. Product is sold strictly for laboratory research purposes. No content on this website should be interpreted as medical or professional advice. Purchasers assume all responsibility for proper handling, storage, and use in accordance with standard laboratory safety protocols. Product is sold only to individuals 18 years of age or older with appropriate laboratory or research experience.